Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene and GELA to commence new Revlimid study

Celgene and GELA to commence new Revlimid study

20th June 2011

Celgene is allying with the Groupe d'Etude des Lymphomes de l'Adulte (GELA) to conduct an international clinical trial of a Revlimid-based follicular lymphoma treatment.

The cooperative adult lymphoma research group has selected Celgene's drug to utilise alongside rituximab as a therapy for newly diagnosed patients in a study designed to evaluate the therapeutic benefits of the treatment.

Revlimid has already been shown to offer significant promise both as a monotherapy and in combination with rituximab across a variety of lymphoma subtypes in previous clinical trials.

Dr Jean Pierre Bizzari, head of global clinical oncology and haematology for Celgene, said the company is looking forward to continuing its collaborative work with one of the world's most prominent lymphoma research groups.

"Looking ahead, this study has true potential to advance non-chemotherapy treatment options for an incurable subtype of lymphoma," he said.

Earlier this month, the firm reported positive data from a phase III study of Abraxane, showing the benefits it offers to non-small cell lung cancer patients.ADNFCR-8000103-ID-800584197-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.